ArticleDiscover oncology2025
HOMER3 and its correlation with immune-infiltrating M2 macrophages in colorectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Homer scaffold protein 3 (HOMER3) is a member of the HOMER family of postsynaptic density scaffolding proteins, but its function in CRC remains unclear. This study aimed to elucidate the role of HOMER3 in CRC by analyzing extensive databases and evaluating real-world clinical samples. Additionally, multivariate Cox regression analysis and functional enrichment analysis were utilized to identify the pathways and functions potentially regulated by HOMER3 and its co-expressed genes. Database analysis unveiled a significant upregulation of HOMER3 in CRC, correlating with diminished survival metrics and adverse clinical indicators such as advanced pT stage and pN stage. Experimental analysis of real-world samples showed that HOMER3 expression was elevated in CRC and was associated with advanced pN and pT stages. Elevated HOMER3 expression emerged as an independent prognostic marker for poorer outcomes in CRC patients. The functional enrichment analysis underscored HOMER3’s oncogenic potential, implicating it in key regulatory mechanisms of tumorigenesis and its association with diverse immune cell infiltration, notably macrophages. We observed a positive correlation between M2 macrophages and HOMER3 expression, a finding that was further corroborated by immunofluorescence staining. HOMER3 may serve as a valuable prognostic biomarker in CRC, and its expression correlates with the infiltration of M2-polarized macrophages within the tumor immune microenvironment. These findings underscore the necessity for further investigations into the functional role of HOMER3 in CRC progression and its underlying immune regulation mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.